Search results for "TUMORS"

showing 10 items of 1138 documents

Survey of third-party parenting options associated with fertility preservation available to patients with cancer around the globe

2018

Purpose In the accompanying article, “Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe,” we showed that specific fertility preservation services may not be offered at various sites around the world because of cultural and legal barriers. We assessed global and regional experiences as well as the legal status of third-party reproduction and adoption to serve as a comprehensive international data set and resource for groups that wish to begin oncofertility interventions. Methods We provide data on the legalities of third-party assisted reproductive technologies and other family-building options in the 28 oncofertility-practicing countries surveyed. R…

Cancer Researchmedicine.medical_specialtyResource (biology)fertility preservationPsychological interventionMEDLINEGlobeReproductive technologylcsh:RC254-28203 medical and health sciences0302 clinical medicineSupportive Care and Quality of LifeNeoplasmsSurveys and QuestionnairesOriginal ReportsJournal ArticlemedicineGlobal healthHumansFertility preservationReferral and ConsultationCancerOncofertility030219 obstetrics & reproductive medicineParentingbusiness.industryHealth Services and OutcomesPublic relationslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensWomen's cancers Radboud Institute for Health Sciences [Radboudumc 17]3. Good healthSurgerymedicine.anatomical_structureOncology030220 oncology & carcinogenesis/dk/atira/pure/researchoutput/pubmedpublicationtype/D016428businessreproductive medicine
researchProduct

Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications

2021

Simple Summary This review proposes a comprehensive overview of the main prognostic systems for HCC classified as prognostic scores, staging systems, or combined systems. Prognostic systems for HCC are usually compared in terms of homogeneity, monotonicity of gradients, and discrimination ability. However, despite the great number of published studies comparing HCC prognostic systems, it is rather difficult to identify a system that could be universally accepted as the best prognostic scheme for all HCC patients encountered in clinical practice. In order to give a contribute in this topic, we conducted a study aimed at externally validate the MESH score and the CNLC classification using the…

Cancer Researchmedicine.medical_specialtyReviewlcsh:RC254-282Prognostic score03 medical and health sciences0302 clinical medicinemedicineIn patientMedical physicsStaging systemmonotonicity of gradientsSettore MED/12 - Gastroenterologiadiscrimination ability; hepatocellular carcinoma; homogeneity; monotonicity of gradients; prognostic performance; prognostic systembusiness.industryprognostic systemExternal validationMono-tonicity of gradienthepatocellular carcinomamedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSettore MED/18homogeneityOncology030220 oncology & carcinogenesisHepatocellular carcinomaPopulation data030211 gastroenterology & hepatologyGeneral healthdiscrimination abilityLiver dysfunctionbusinessprognostic performanceCancers
researchProduct

Assessing Preferences in Patients with Head and Neck Squamous Cell Carcinoma: Phase I and II of Questionnaire Development.

2020

Shared-decision making for head and neck squamous cell carcinoma (HNSCC) is challenged by the difficulty to integrate the patient perception of value within the framework of a multidisciplinary team approach. The aim of this study was to develop a questionnaire to assess the preferences of HNSCC patients with respect to the disease trajectory, expected treatment, and toxicities. In accordance with the standardized EORTC Quality of Life Group&rsquo

Cancer Researchmedicine.medical_specialtyScoring criteriaDiseaselcsh:RC254-282Article03 medical and health sciences0302 clinical medicineQuality of lifehead and neck cancer; multimodal therapies; patient preferences; patient priorities; quality of lifeHealth caremedicineIn patient030212 general & internal medicinemultimodal therapiesneoplasmsbusiness.industryHead and neck cancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensHead and neck squamous-cell carcinoma3. Good healthstomatognathic diseasesPatient perceptionsOncologypatient prioritiesquality of life030220 oncology & carcinogenesisFamily medicinehead and neck cancerbusinesspatient preferences
researchProduct

Recent Advances in the Treatment of Patients with Multiple Myeloma

2020

Simple Summary The evolving data from trials assessing novel combinations as a part of the frontline and relapse treatment in transplant and non-transplant candidates have markedly improved the anti-myeloma efficacy of the different therapeutic regimens and improved patients’ prognosis. Current treatment objectives are focused to further improve the rate of complete remission, time to progression, progression-free survival and overall survival without increasing toxicity. Besides, different strategies are being developed in the elderly population as this group of patients requires a closer monitoring with individualized, dose-modified regimens to improve tolerability while maintaining their…

Cancer Researchmedicine.medical_specialtyautologous stem cell transplantationmedicine.medical_treatmentHematopoietic stem cell transplantationDiseaseNewly diagnosedReviewlcsh:RC254-282maintenance03 medical and health sciences0302 clinical medicineAutologous stem-cell transplantationmedicinecar-t cellsIntensive care medicineMultiple myelomanovel drugsbusiness.industryrelapsed refractory multiple myelomaearly relapseAdvanced stageImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensClinical trialmultiple myelomalate relapseOncology030220 oncology & carcinogenesisimmunotherapybusinessconsolidation030215 immunologyCancers
researchProduct

Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function

2021

A combination of albumin-bilirubin (ALBI) grading and the Prognostic Nutritional Index (PNI) was identified recently as a highly predictive tool for patients with hepatocellular carcinoma (HCC) undergoing tumor ablation. The present study evaluated this combination in patients undergoing transarterial chemoembolization (TACE). Between 2010 and 2020, 280 treatment-naïve patients were retrospectively identified. The influence of ALBI grade, PNI and the novel ALBI-PNI on the median overall survival (OS) was assessed. In the next step, the prognostic ability of the combined approach was compared to established scoring systems. Both ALBI grade 2−3 and a low PNI were highly predictive for median …

Cancer Researchmedicine.medical_specialtybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensalbumin-bilirubin gradehepatocellular carcinomatransarterial chemoembolizationprognostic nutritional indexmedicine.diseaseGastroenterologyConcordance indexCombined approachTumor ablationArticlerisk predictionOncologyInternal medicineHepatocellular carcinomamedicineOverall survivalIn patientLiver functionbusinessGrading (tumors)RC254-282Cancers
researchProduct

A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) …

2013

4031 Background: The novel somatostatin analog (SSA) pasireotide has a broader binding profile than currently available SSA (octreotide and lanreotide). Results from a phase III study (NCT00690430) of pasireotide LAR (P) vs octreotide LAR (O) in patients (pts) with NET and disease-related symptoms uncontrolled by the maximum approved dose of available SSA are shown. Methods: Pts (N=110) were randomized and stratified by predominant symptom at baseline (diarrhea [D], flushing [F], or D+F) 1:1 to P (60 mg IM) or O (40 mg IM) q28d. Primary objective was symptom response at month (M) 6. Secondary objectives included tumor response and safety. Progression-free survival (PFS) was an exploratory …

Cancer Researchmedicine.medical_specialtybusiness.industryOctreotideDiseaseNeuroendocrine tumorsmedicine.diseaseLanreotideOctreotide larGastroenterologyPasireotidechemistry.chemical_compoundSomatostatinEndocrinologyOncologychemistryInternal medicineMedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: Real-life experience from the French CAREPI study group

2021

Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemiplimab. Endpoints were best overall response rate (BOR), progression-free survival (PFS), overall survival (OS), duration of response (DOR) and safety. The 245 patients (mean age 77 years, 73% male, 49% prior systemic treatment, 24% immunocompromised, 27% Eastern Cooperative Oncology Group performance status (PS) ≥ 2) had laCSCCs (35%) or mCSCCs (65%). For the 240 recipients of ≥1 infusion(s), the BOR was 50.4% (complete, 21%

Cancer Researchmedicine.medical_specialtycutaneous squamous cell carcinomaLocally advancedBest Overall Response[SDV.CAN]Life Sciences [q-bio]/CancerGastroenterologyArticle030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicineOverall survivalMedicineAdverse effectGroup performanceRC254-282Immune statusbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensMean agemedicine.diseasechronic dermatosisToxic epidermal necrolysis3. Good healthimmunocompromisedreal-life settingOncology030220 oncology & carcinogenesisPD-1–blocking antibodycemiplimabbusiness[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
researchProduct

Cancer and Pregnancy: A Comprehensive Review

2021

Simple Summary The co-occurrence of cancer and pregnancy is fortunately a rare event. It is a challenging situation for all involved parties, as the risks and benefits of oncological treatments should be balanced for both the mother and the offspring. This work offers guidance to clinicians regarding the choice of diagnostic and therapeutic procedures, as well as regarding the management of the pregnancy. Abstract Cancer diagnosis and treatment in pregnant women is a challenging situation. A multidisciplinary network of specialists is required to guide both, the expecting mother and the unborn child through the diagnostic workup and the cytotoxic therapy, by balancing the respective risks a…

Cancer Researchmedicine.medical_specialtydiagnostic proceduresfetal outcomeReviewtherapeutic procedures03 medical and health sciences0302 clinical medicineUnborn childMultidisciplinary approachmedicinecancer030212 general & internal medicineRisks and benefitsStage (cooking)Intensive care medicineCytotoxic TherapyRC254-282PregnancyNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancermedicine.diseaseOncology030220 oncology & carcinogenesisFetal outcomepregnancyCancers
researchProduct

Hypofractionated Radiotherapy in Head and Neck Cancer Elderly Patients: A Feasibility and Safety Systematic Review for the Clinician

2021

ObjectiveRadiotherapy (RT) in the head and neck (H&N) site are undoubtedly the most challenging treatments for patients. Older and frail patients are not always able to tolerate it, and there are still no clear guidelines on the type of treatments to be preferred for them. The recommendations for Risk-Adapted H&N Cancer Radiation Therapy during the coronavirus disease 2019 (COVID-19) pandemic provided by the ASTRO-ESTRO consensus statement achieved a strong agreement about hypofractionated RT (HFRT). A systematic literature review was conducted in order to evaluate the feasibility and safety of HFRT for older patients affected by H&N malignancies.Materials and Method…

Cancer Researchmedicine.medical_specialtyelderly oncologymedicine.medical_treatmentelderlyEffective dose (radiation)medicinegeriatric oncologyRC254-282radiotherapyPerformance statushypofractionationbusiness.industryHead and neck cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseRadiation therapyRegimenSystematic reviewOncologyGeriatric oncologyConcomitanthead and neck cancerSystematic ReviewRadiologybusinessFrontiers in Oncology
researchProduct

Intermittent and Periodic Fasting, Hormones, and Cancer Prevention

2021

Simple Summary Hormonal and growth factor alterations, related to an elevated food consumption and excessive adiposity, affect the regulation of genes involved in cellular processes including proliferation, differentiation and DNA repair, allowing cells to survive and proliferate despite the accumulation of mutations which lead to malignant transformation. The growth hormone/insulin growth factor-1 (GH/IGF-1)/ insulin pathway and its downstream effectors, in fact, are known to promote aging and/or age-related diseases, including cancer, in many model organisms. The restriction of nutrients is established to have strong effects on levels of hormones and growth factors, delaying the incidence…

Cancer Researchmedicine.medical_specialtyfastingDNA damagemedicine.medical_treatmentReviewInternal medicinemedicineRC254-282Cancer preventioncancer preventionbusiness.industryInsulinRegeneration (biology)agingNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerImmunosenescencemedicine.diseasegrowth hormonesEndocrinologyOncologyCancer cellDNA damagebusinessHormoneCancers
researchProduct